Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zai Lab Ltd ( (HK:9688) ) has issued an update.
Zai Lab reported a 15% increase in net product revenue to $457.2 million for 2025, driven by strong demand and broader hospital adoption for XACDURO and higher sales of NUZYRA, despite some supply constraints. The company’s net loss narrowed by 32% to $175.5 million, as revenue growth outpaced operating costs and foreign currency movements shifted from losses to gains.
Operating efficiency efforts led to a 6% reduction in research and development expenses to $220.9 million and a 7% decline in selling, general and administrative costs to $277.6 million, even as clinical trial expenses increased. Basic and diluted loss per share improved to $0.16 from $0.26, highlighting progress toward profitability while maintaining investment in the pipeline under U.S. GAAP-compliant financial reporting reviewed and audited in Hong Kong.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong, focused on developing and commercializing innovative medicines. Its portfolio includes anti-infective products such as XACDURO and NUZYRA, targeting growing patient demand and expanding hospital and market coverage in its core territories.
Average Trading Volume: 9,656,369
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.57B
For detailed information about 9688 stock, go to TipRanks’ Stock Analysis page.